Cancer Treatment Reviews

Papers
(The TQCC of Cancer Treatment Reviews is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review223
Systemic therapy for older patients with early breast cancer216
Editorial Board203
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)196
Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty141
Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer128
Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis119
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives116
De-escalating adjuvant therapies in older patients with lower risk estrogen receptor-positive breast cancer treated with breast-conserving surgery: A systematic review and meta-analysis107
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer104
The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas99
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint in88
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials84
Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group76
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer75
Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis74
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?74
Editorial Board73
Emerging antibody-based therapies for the treatment of acute myeloid leukemia69
Optimizing care in early phase cancer trials: The role of palliative care66
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis65
Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches64
First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features62
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev.61
If it’s a target, it’s a pan-cancer target: Tissue is not the issue58
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC57
Uncertainties and controversies in axillary management of patients with breast cancer57
Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges56
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials55
Editorial Board54
Havoc in harmony: Unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment52
Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck51
Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes50
Roadmap to cure multiple myeloma49
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations48
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?47
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review44
Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design44
The immunogram of inflammatory breast cancer44
Editorial Board44
HER-2 directed therapies across gastrointestinal tract cancers – A new frontier43
Overview of BH3 mimetics in ovarian cancer43
Extracellular vesicles and the “six Rs” in radiotherapy42
Deciphering primary acinic cell carcinoma of the Breast: Insights from a comprehensive case series and Systematic review41
Managing strategies of chemotherapy and radiotherapy-induced oral mucositis41
Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma40
Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada40
TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC)40
De-escalation of axillary irradiation for early breast cancer – Has the time come?39
Optimizing outcomes and personalizing care with targeted agents in advanced cholangiocarcinoma39
Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside38
The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features38
Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities38
European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer36
Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis36
Editorial Board36
The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives36
Systematic review of the CUP trials characteristics and perspectives for next-generation studies35
Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review35
Malignant ascites: Current therapy options and treatment prospects34
Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies34
Agnostic drug development revisited34
Bone complications of cancer treatment34
Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN)33
Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer33
Editorial Board32
Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer32
Editorial Board31
Acknowledgement to Reviewers 202131
Maintenance therapy after first-line platinum-based chemotherapy in gastroenteropancreatic neuroendocrine carcinomas: A literature review31
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?31
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review30
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis30
Local control strategies for management of NSCLC with oligoprogressive disease29
Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification29
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?29
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications28
Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review28
Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers28
Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review27
Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes27
Corrigendum to “SELNET clinical practice guidelines for soft tissue sarcoma and GIST” [Cancer Treat. Rev. 102 (2021) 102312]26
Engineering strategies to optimise adoptive cell therapy in ovarian cancer26
Pharmacotherapy for leptomeningeal disease in breast cancer26
Comparative efficacy and safety of pyrotinib plus trastuzumab versus trastuzumab plus pertuzumab and trastuzumab monotherapy in neoadjuvant treatment of HER2-positive breast cancer: A systematic revie26
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges26
Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS – GROUP). Part I26
KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond26
Chemotherapy in pancreatic ductal adenocarcinoma: When cytoreduction is the aim. A systematic review and meta-analysis25
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project25
Radiotherapy dose escalation using endorectal brachytherapy in elderly and frail patients with rectal cancer unsuitable for surgery: Lessons from studies in fit patients and future perspectives24
Review: Targeting EZH2 in neuroblastoma24
PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence24
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer24
Evolving immunotherapeutic solutions for triple-negative breast carcinoma24
Selecting systemic treatment for metastatic neuroendocrine tumors of the lung—current evidence and clinical implications23
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis23
Editorial Board23
Strategies for improving detection of circulating tumor DNA using next generation sequencing23
Editorial Board23
Patient-reported outcome measure to implement routine assessment of cancer survivors’ unmet needs: An overview of reviews and COSMIN analysis23
Treatments for relapsed, BRCA-wild type, platinum-sensitive ovarian cancer: A systematic review and network meta-analysis22
Key decision factors in second-line therapy: Expert insights on HR+/HER2-metastatic breast cancer post-CDK4/6 inhibitor progression22
Challenges and perspectives in the management of BRAF-mutated metastatic melanoma: Systemic treatment sequencing and brain metastases22
Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature21
Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis21
Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies21
SELNET clinical practice guidelines for soft tissue sarcoma and GIST21
Identification of the PROMs used to assess ICI toxicities and HRQoL in patients receiving immune checkpoint inhibitor treatment in cancer care and their suitability: A systematic review21
Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives21
Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors21
Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment21
A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors20
Editorial Board20
Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review20
Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives20
Editorial Board20
Editorial Board20
Considerations regarding a network meta-analysis of targeted therapies for BRAF-mutant unresectable or metastatic melanoma20
Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)19
Therapeutic implications of the metabolic changes associated with BRAF inhibition in melanoma19
A systematic review of eHealth technologies for breast cancer supportive care19
Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?19
Corrigendum to “Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)” [Cancer Treatment Reviews 123 (2024) 102672]19
Combination therapies in patients with favorable risk metastatic renal cell Carcinoma: A Systematic Review and Meta-Analysis19
0.070188045501709